FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response in Patients With Cervical Cancer

Cervical Cancer Clinical Trial

Official title:

FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response to Concurrent Radiation Therapy and Chemotherapy in Patients With Cervical Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02317302
• Other study ID #: 201104322
• Status: Terminated
• Phase: Phase 1
• Start date: June 28, 2011
• Est. completion date: June 2, 2020

Study information

• Verified date: June 2020
• Source: Washington University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study, 50 evaluable patients will undergo one FDG-PET study during their chemoradiation, in addition to the standard of care pretreatment and 3-month post-treatment clinical FDG-PET/CT or FDG-PET/MR scans. From all FDG-PET studies, tumor volume, SUVmax, FDGhetero, and texture maps will be obtained. Evaluating the changes in tumor SUVmax and heterogeneity during treatment will aid in better understanding the role of these biological parameters in inadequate response to chemoradiation. Other researchers, using MRI imaging, have evaluated changes in the cervical tumor volume during treatment. The investigators expect there will be variation in how cervical tumors shrink and change during chemoradiation and therefore we are going to use multiple measures in addition to tumor volume to evaluate cervical tumor metabolic heterogeneity. Being able to predict at diagnosis the patients who are at higher risk for persistent disease following chemoradiation would allow for future studies where these high risk patients could be specifically targeted with more aggressive therapy.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 48
• Est. completion date: June 2, 2020
• Est. primary completion date: June 2, 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient must have biopsy-proven cervical cancer (FIGO stage-Ib2-IVb).

• Patient must be at least18 years of age.

• Patient must be planning to receive chemoradiation therapy with cisplatin.

• Patient must have non-pregnant status if a female of childbearing potential. Women who have had a tubal ligation at least 12 months prior to study entry or a hysterectomy will be considered NOT of childbearing potential. Postmenopausal women must have been amenorrheic for at least 12 consecutive months to be considered NOT of childbearing potential.

• Patient may have distant metastatic disease provided the estimated survival is at least 1 year.

• Patient's tumor(s) must be FDG avid on baseline standard of care FDG-PET/CT or PET/MR imaging that was performed at Barnes-Jewish Hospital Clinical PET Facility.

• Patient must be able and willing to give informed consent.

• If the patient will be scanned on the PET/MR for the mid-treatment scan, they must be determined to be safe for exposure to the magnetic field. This will be determined the day of imaging by the technologist with the use of a screening form. If a patient is not safe for the PET/MR scanner, their mid-treatment images will occur on the PET/CT scanner in the Center for Clinical Imaging Research.

Exclusion Criteria:

• Patient must have no other active cancer at the time of diagnosis of cervical cancer.

• Patient cannot have received treatment for any malignancy, with the exception of non-melanoma skin cancer, in the past 5 years.

• Patient must not be an uncontrolled diabetic with a glucose of = 200mg/dl at the time of PET imaging.

Related Conditions & MeSH terms

• Cervical Cancer
• Uterine Cervical Cancer
• Uterine Cervical Neoplasms

Intervention

Device:
• FDG-PET/MR

• FDG-PET/CT

Locations

Country	Name	City	State
United States	Washington University School of Medicine	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in FDG heterogeneity (Using texture analysis)	Using texture analysis	Up to 5 years
Primary	Change in SUVmax (SUVmax - maximum standardized uptake value = is a marker of tumor glucose metabolism and reflects tumor aggressiveness)	SUVmax - maximum standardized uptake value = is a marker of tumor glucose metabolism and reflects tumor aggressiveness.	Up to 5 years
Secondary	Response to therapy based on FDG heterogeneity		Up to 5 years
Secondary	Response to therapy based on SUVmax		Up to 5 years

External Links

•   Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine